X4 Pharmaceuticals was one of the legions of pre-commercial biopharma companies which slashed its headcount and budgets last year, but now the firm looks on track for its first ever drug approval.
X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs
Cost-Cutting And Focus On Lead Asset Pays Off
X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.

More from Business
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.